Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2008

View Archived Issues

Recent Takeda patent reports novel proton pump inhibitors

New anticancer agents imparted in recent patent literature

New GSK-3beta inhibitors revealed in Bayer patent

BiovaxID study shows it prolongs cancer-free survival

Omrix provides interim analysis data for Fibrin Pad in mild to moderate bleeding

Evotec commences phase I trials with P2X7 antagonist

Protox presents positive 12-month data from BPH study

NIAID awards contract to IBT to develop vaccine against Ebola and Marburg viruses

Biothera completes enrollment in first arm of phase Ib/IIa trial of Imprime PGG and Erbitux

Neotropix initiates enrollment into expanded clinical trial of NTX-010 in neuroendocrine cancer

Marinus presents update on phase II clinical trials of ganaxolone in epilepsy

3M licenses TLR agonist compounds to sanofi pasteur as vaccine adjuvants

Biomarker analysis shows potential of p38 MAPK inhibitor SB-681323 in COPD

EVEREST trial: Tolvaptan beneficial in heart failure patients with renal impairment and hypotension

Similar 1-year survival seen in 3 studies of ipilimumab-treated metastatic melanoma patients

Disease stabilization seen with vatalanib in metastatic melanoma patients

Biofrontera completes treatment and evaluation in phase III BF-200 ALA trial

Phase I trial of Inspire's INS-117548 for glaucoma begins

QLT initiates phase I trial of synthetic retinoid product QLT-091001

NCCN, Abraxis and AstraZeneca enter collaboration to conduct studies of Abraxane

Invitrogen notifies European Commission of pending merger with Applied Biosystems

Icagen initiates phase II proof-of-concept trial for senicapoc in allergic asthma

R&D highlights from the UBS Global Life Sciences Conference in New York: Santhera Pharmaceuticals

Santhera launches Catena in Canada for Friedreich's ataxia

Shionogi's acquisition of Sciele complete

DeveloGen completes phase I trial of somatostatin analogue DG-3173 for acromegaly

Circassia acquires North American and Japanese rights to dopexamine from Ipsen

P144 TGF-beta1 inhibitor safe in phase I study in healthy volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...